drugset / Trial / NCT00002920
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
Phase 3
Completed
313 enrolled
SWOG Cancer Research Network
Cancer and Leukemia Group B · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ, lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II breast cancer and who are taking tamoxifen.
Timeline
- Start
- 1997-03
- Primary completion
- 2006-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | medroxyprogesterone acetate | Other / unclassified | — | Oral |
| Background | Tamoxifen | Small molecule | — | Oral |